Compare Incyte Corporation (INCY) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares Ultra QQQ ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while ProShares Ultra QQQ ETF trades at $98.43 (market cap $15.38B). The key difference: Incyte Corporation is the larger of the two by market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| INCY | QLD | |
|---|---|---|
Market Cap | $22.85B | $15.38B |
Volume | 1,927,029 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $100.77 |
52-Week Low | $83.80 | $57.16 |
Typical Hold Time | 33 Days | 36 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
QLD trades at $98.43, down 1.8% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains key support at $96 with resistance at $100. Recent news highlights QLD's resilience compared to higher-leverage alternatives during market downturns, with institutional buying activity noted in recent filings.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face volatility risks from Federal Reserve policy and Nasdaq concentration. QLD's 2x leverage strategy offers a middle ground for Nasdaq-100 exposure, but requires careful risk management during market stress periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
